http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shin, Jin Soo,Do Hwang, Seon,Kim, Hyun Soo,Cho, Sung Whan,Seo, Sang Heui Mary Ann Liebert, Inc ; Mary Ann Liebert, Inc ; OC 2010 VIRAL IMMUNOLOGY Vol.23 No.4
<P>Abstract Swine-origin pandemic 2009 A (H1N1) influenza viruses are still infecting humans, and humans are currently being vaccinated with the inactivated vaccine of 2009 A (H1N1) influenza virus. We wanted to determine the efficacy of 2009 A (H1N1) inactivated vaccine in ferrets. Ferrets immunized with one dose (7.5 mug) of 2009 A (H1N1) inactivated vaccine were not protected from infections of either pandemic H1N1 or seasonal H1N1 influenza viruses, while ferrets immunized with two doses of 2009 A (H1N1) inactivated vaccine were protected from infections of pandemic H1N1, but not seasonal H1N1 influenza viruses. IgG subtype of antibody was dominantly detected in tissues of immunized ferrets. Our study suggests that pandemic H1N1 vaccine may not elicit the antibody cross-reactive to the seasonal H1N1 influenza virus.</P>
Shin, Jin Soo,Kim, Hyun Soo,Cho, Sung Hwan,Seo, Sang Heui Mary Ann Liebert, Inc ; Mary Ann Liebert, Inc ; OC 2010 VIRAL IMMUNOLOGY Vol.23 No.3
<P>Outbreaks of highly pathogenic H5N1 influenza viruses have been reported in many countries worldwide. The possibility of pandemics caused by H5N1 influenza viruses is high since human infections by H5N1 viruses continually occur. In this study we determined the immune response and efficacy of inactivated H5N1 vaccine developed by reverse genetics in ferrets. Ferrets intramuscularly inoculated with two doses of H5N1 vaccine survived the lethal challenge with homologous or heterologous H5N1 influenza viruses, while 75% and 25% of ferrets immunized with one dose of H5N1 vaccine survived the lethal challenge with homologous and heterologous H5N1 influenza viruses, respectively. When we determined antibody subtypes specific for H5N1 influenza viruses in tissues and sera of vaccinated ferrets, IgG antibodies were detected mainly in the trachea, nostril, lung, heart, liver, kidney, intestine, spleen, and serum. Our results suggest that IgG antibodies may play a major role in protecting ferrets immunized with the inactivated H5N1 vaccine from lethal challenge with H5N1 influenza viruses.</P>
Development of a <sup>177</sup>Lu-Labeled RGD Derivative for Targeting Angiogenesis
Ju, Chang Hwan,Jeong, Jae Min,Lee, Yun-Sang,Kim, Young Joo,Lee, Byung Chul,Lee, Dong Soo,Chung, June-Key,Lee, Myung Chul,Jeong, Seo Young Mary Ann Liebert 2010 Cancer Biotherapy & Radiopharmaceuticals Vol.25 No.6
<P>Abstract Various Arg-Gly-Asp (RGD) derivatives have been labeled with various radioisotopes for targeting 관(v)관(3) integrin, which is expressed during angiogenesis in tumor. In this study, 2-(4'-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA-SCN) and its c(RGDyK) conjugate (NOTA-SCN-c(RGDyK)) were labeled with (177)Lu, which is a near ideal radionuclide for treating tumors because it emits therapeutic beta particles and gamma rays for monitoring. (177)Lu (250?Bq) was labeled with 50? NOTA-SCN-c(RGDyK) quantitatively. The specific activity of (177)Lu-NOTA-SCN-c(RGDyK) was 1.44??10(5) Ci/mol. Biodistribution study was performed in Balb/c mice xenografted with CT-26 (mouse colon cancer) cells. The highest uptake was found in kidneys (7.56%??0.71% ID/g at 1 hour), and tumor uptake was 1.70%??0.33% ID/g at 1 hour postinjection. Moderate tumor-to-blood (2.36??0.29) and tumor-to-muscle (2.06??0.40) ratios were observed. This study shows that (177)Lu-NOTA-SCN-c(RGDyK) is a potential therapeutic agent for angiogenic tumors, but special care is required to prevent kidney toxicity.</P>
Han, Kyung Seok,Joung, Jae Young,Cho, Kang Su,Seo, Ho Kyung,Chung, Jinsoo,Park, Won Seo,Lee, Kang Hyun Mary Ann Liebert 2008 Journal of endourology Vol.22 No.12
<P>BACKGROUND AND PURPOSE: We evaluated the results of a second transurethral resection (TUR) performed in patients referred after an initial TUR for nonmuscle invasive bladder cancer. PATIENTS AND METHODS: From April 2001 to January 2008, patients who were referred for a second opinion and who underwent a second TUR at our institution were included in this study. Patients who had noninvasive bladder cancer and received the second TUR less than 8 weeks after the initial TUR were included in this analysis. The presence of residual tumor and changes of stage or grade from the two different TUR procedures were recorded and analyzed. RESULTS: Fifty-six patients were evaluated in this study. The initial TUR specimens included the muscularis propria layers in 17 cases (30.4%), while the second opinion TUR specimens included the proper muscle layers in 47 cases (83.9%). Residual tumor was present in 16 of 25 (64.0%) patients with T(a) bladder cancer and in 20 of 30 (66.7%) patients with T(1) bladder cancer. Overall upstaging by the second TUR occurred for 9 patients (16.1%). Of 25 patients with T(a) bladder cancer, the second TUR confirmed the lamina propria invasion in one (4.0%) and muscle invasion in one (4.0%). The second TUR confirmed the muscle invasion in 7 of 30 (23.3%) patients with T(1) bladder cancer. Nine patients (16.1%) had their treatment strategy changed. CONCLUSION: The previous results and our experiences suggest that a second TUR is recommended to reduce the chance of residual tumor and staging error because of nonstandardized TUR in the patients referred to an academic or referral center for a second opinion, irrespective of previous tumor stage.</P>
Clinical, Histopathological, and Molecular Characteristics of Papillary Thyroid Microcarcinoma
Lim, Dong-Jun,Baek, Ki-Hyun,Lee, Youn-Soo,Park, Woo-Chan,Kim, Mee-Kyoung,Kang, Moo-Il,Jeon, Hae-Myung,Lee, Jong-Min,Yun-Cha, Bong,Lee, Kwang-Woo,Son, Ho-Young,Kang, Sung-Koo Mary Ann Liebert 2007 Thyroid Vol.17 No.9